Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
The onset of heart failure is typically preceded by cardiac hypertrophy, a response of the
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …
heart to increased workload, a cardiac insult such as a heart attack or genetic mutation …
The war against heart failure: the Lancet lecture
E Braunwald - The Lancet, 2015 - thelancet.com
Heart failure is a global problem with an estimated prevalence of 38 million patients
worldwide, a number that is increasing with the ageing of the population. It is the most …
worldwide, a number that is increasing with the ageing of the population. It is the most …
CaMKII is a RIP3 substrate mediating ischemia-and oxidative stress–induced myocardial necroptosis
T Zhang, Y Zhang, M Cui, LI **, Y Wang, F Lv, Y Liu… - Nature medicine, 2016 - nature.com
Regulated necrosis (necroptosis) and apoptosis are crucially involved in severe cardiac
pathological conditions, including myocardial infarction, ischemia-reperfusion injury and …
pathological conditions, including myocardial infarction, ischemia-reperfusion injury and …
Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in …
T Suetomi, A Willeford, CS Brand, Y Cho, RS Ross… - Circulation, 2018 - Am Heart Assoc
Background: Inflammation is associated with cardiac remodeling and heart failure, but how it
is initiated in response to nonischemic interventions in the absence of cell death is not …
is initiated in response to nonischemic interventions in the absence of cell death is not …
CaMKII as a therapeutic target in cardiovascular disease
CaMKII (the multifunctional Ca2+ and calmodulin-dependent protein kinase II) is a highly
validated signal for promoting a variety of common diseases, particularly in the …
validated signal for promoting a variety of common diseases, particularly in the …
Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies
Cardiac hypertrophy can be defined as an increase in heart mass. Pathological cardiac
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …
hypertrophy (heart growth that occurs in settings of disease, eg hypertension) is a key risk …
Regulation of cardiac hypertrophy by intracellular signalling pathways
The mammalian heart is a dynamic organ that can grow and change to accommodate
alterations in its workload. During development and in response to physiological stimuli or …
alterations in its workload. During development and in response to physiological stimuli or …
Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation
Abstract Ca2+/calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important
regulatory functions in the heart and brain, and its chronic activation can be pathological …
regulatory functions in the heart and brain, and its chronic activation can be pathological …
Molecular pathways underlying cardiac remodeling during pathophysiological stimulation
Cardiac remodeling involves molecular, cellular, and in-terstitial changes that manifest
clinically as changes in size, shape, and function of the heart after injury or stress …
clinically as changes in size, shape, and function of the heart after injury or stress …
Signaling effectors underlying pathologic growth and remodeling of the heart
Cardiovascular disease is the number one cause of mortality in the Western world. The heart
responds to many cardiopathological conditions with hypertrophic growth by enlarging …
responds to many cardiopathological conditions with hypertrophic growth by enlarging …